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Background. Aggressive natural killer cell leukemia (ANKL) is extremely rare and habitually manifests as a systemic disease with
multiorgan failure that rapidly evolves to death. The neoplastic natural killer (NK) cells usually harbor the Epstein-Barr virus
(EBV) with a latent viral infection pattern type II; they often have a cytoplasmic CD3𝜀+ and surface CD3−, CD2+, and CD56+
immunophenotype, and they show complex genetic abnormalities affecting multiple tumor suppressor genes and oncogenes.
We present a rare case of CD56-negative ANKL and review the clinical and laboratorial criteria for the diagnosis, as well as
the available therapies. Case Presentation. A European 36-year-old male presented with acute onset fever, pallor, weakness, and
jaundice. He had hepatosplenomegaly, severe pancytopenia, hepatic cytolysis, and very high serum lactic dehydrogenase levels.
The bone marrow studies resulted in the diagnosis of an EBV-positive, CD56-negative ANKL. The patient failed to respond to
gemcitabine and cisplatin-based polychemotherapy, dying threemonths later with leukemicmeningitis andmultiple cranial nerves
palsies. Conclusions. The diagnosis of ANKL is difficult and requires both clinical suspicion and an extensive laboratorial approach.
Absence of CD56 expression on the neoplastic NK cells may impose difficulties in the diagnosis, which requires morphological,
immunophenotypic, histopathological, immunohistochemical, cytogenetic, and molecular studies.
1. Background
Natural killer (NK) cell neoplasms are classified by the
World Health Organization (WHO) into aggressive NK cell
leukemia (ANKL) [1], extranodal NK/T cell lymphoma, nasal
type (ENKTL) [2], and chronic lymphoproliferative disorders
of NK cells [3], the latter being considered provisionally.
ENKTL and ANKL are rare diseases, with higher prevalence
in Asia and Central and South America. ENKTL usually
present as a destructive tumor affecting the nose and upper
aerodigestive tract or any organ or tissue in the body [4,
5]. ANKL is a very rare disease which comprises less than
0.1% of all lymphoid neoplasms [6] and usually manifests
as a systemic disease with multiorgan involvement. The
histopathological hallmark of these aggressiveNKcell tumors
is a polymorphic neoplastic infiltrate with angiocentric-
ity, angiodestruction, and tissue necrosis. The tumor cells
have cytoplasmic azurophilic granules containing cytotoxic
molecules and they usually show a CD45+, CD2+, sCD3−,
cytCD3𝜀+, CD56+, and CD16−/+ immunophenotype and
Epstein-Barr virus- (EBV-) encoded membrane proteins; in
addition, EBV-encoded small RNAs (EBERs) are usually
detected on lymphoma cells by in situ hybridization, and
complex chromosomal abnormalities are frequent.The rarity
of the NK cell tumors limits our ability to standardize the
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procedures for the diagnosis and treatment and efforts should
be made to encourage multi-institutional registries.
From the review of relevant literature, the patient
reported herein is one of the rare cases of ANKLwith aCD56-
negative immunophenotype, the final event being meningeal
infiltration with compromise of multiple cranial nerves;
other clinical, laboratory, and biological features were those
typically observed in this aggressive NK cell malignancy.
2. Case Presentation
2.1. Disease Presentation. A 36-year-old Caucasian Por-
tuguese male was admitted to the hospital in October
2010, with fever (38∘C), pallor, weakness, and jaundice.
His medical history revealed chronic alcohol abuse. The
physical examination showed hepatosplenomegaly and there
were no palpable superficial lymph nodes. Blood counts
demonstrated pancytopenia: white blood cells 1.80 × 109/L,
neutrophils 0.69 × 109/L, lymphocytes 0.64 × 109/L (no
evidence for morphologically abnormal cells), platelets
46 × 109/L, and hemoglobin 6.6 g/dl. Biochemistry analysis
revealed markedly increased serum lactate dehydrogenase
levels (LDH) 2815 IU/L (135–225 IU/L) and abnormal liver
tests: total bilirubin (TB) 1.5mg/dl (<1.2mg/dL), aspartate
transaminase (AST) 124 IU/L (10–37 IU/L), alanine transam-
inase (ALT) 62 IU/L (10–31 IU/L) and gama-glutamil trans-
ferase (GGT) 107 IU/L (10–49 IU/L); coagulation tests were
normal. The abdominal computerized tomography (CT)
scan confirmed the hepatosplenomegaly (liver and spleen
longitudinal axis of 209 cm and 158 cm, resp.) and did not
show other abnormalities (Figure 1(a)).
2.2. Laboratorial Investigation. The bone marrow (BM) aspi-
rate had more than 80% of morphologically immature cells,
with a pale or slightly basophilic cytoplasm sometimes with
fine azurophilic granules and a nucleus with an immature
chromatin, with one or two distinct nucleoli, and the first
hypothesis for the diagnosis was that of an acute leukemia
(Figure 2).
Flow cytometry (FCM) analysis of the BM aspirate cells
using the EuroFlow lymphoid screening tube (LST) and
antibody panel for NK cell chronic lymphoproliferative dis-
eases (NK-CLPD) [7], complemented with other cell surface
markers, showed that the neoplastic cells were positive for
CD45 (high), CD2, CD26, CD38, CD94 (high), and HLA-
DR (high, heterogeneous) antigens, and negative for surface
CD3, TCR, CD4, CD5, CD7, CD8, CD11b, CD11c, CD16,
CD56, CD57, and CD161, as well as for cytoplasmic CD3; in
addition, they express intracellular granzyme B and perforin
(Figure 3). B cell (CD19, CD20, and CD79a), myeloid (CD13,
CD14, CD15, CD64, CD65, and myeloperoxidase), immature
(CD34, TdT), and dendritic (CD123) cell associated markers
were all negative (data not shown). In the PB there were
10%of phenotypically abnormalCD45+high, CD2+, CD16+low,
CD94+high, and HLA-DR+ NK cells, 19% of which expressed
dimly and heterogeneously the CD56 molecule, at levels that
were much lower than those observed in normal PB NK cells
(data not shown). Flow cytometry propidium iodide based
NK cell DNA studies revealed a diploid cell DNA content
(DNA index 1.02) and a high proliferative rate (G0/G1 phases:
67.4%; S phase: 31.8%;G2/Mphases: 0.8%). PolymeraseChain
Reaction (PCR) TCRG gene rearrangements studies were
consistent with a germ-line configuration.
The BM biopsy revealed a hypercellular marrow
infiltrated by CD45+, cytoplasmic CD3𝜀+, EBER+ and
CD56, CD34, CD20, CD68, myeloperoxidase, and lysozyme-
negative atypical lymphoid cells, interpreted individually
given rise to the possibility of an immature EBV+ T cell
leukemia (Figure 4).
The BM karyotype with chromosome banding anal-
ysis showed complex aberrancies: 46,add(X)(q27),-Y,i(7q),
+8,add(17)(p13),add(19)(q13) (Figure 5).
Infection markers were negative for human immunodefi-
ciency virus types 1 and 2, viral hepatitis B and C, and human
T cell lymphotropic virus types 1 and 2. The whole blood
EBV load, detected by quantitative PCR for viral DNA, was
of 57 × 105 copies/ml.
As noneurologic symptomswere present, central nervous
system involvement was not evaluated.
2.3. Diagnosis. In view of these findings and according to the
WHO classification of neoplasms of the hematopoietic and
lymphoid tissues [1], the final diagnosis was an EBV+ ANKL,
Ann Arbor stage IVB, high risk NKIPI (NK/T cell lymphoma
international prognostic index), ECOG status 4.
2.4. Treatment andDisease Evolution. Thepatient was treated
with a combination of gemcitabine (1 g/m2 days 1, 8, and 15),
cisplatin (100mg/m2 day 15), and methylprednisolone (1 g
days 1–5) (GEM-P) repeated every 28 days [8].
The first BM reevaluation, performed on day 23 after the
first chemotherapy course, revealed 0.5% of phenotypically
abnormal (CD2+, CD56−, CD94+, and HLA-DR+) NK cells
and a normal karyotype (46, XY). In addition, there was
a marked decrease in the EBV load in the PB to 4 ×
105 (day 14) persisting at 6.6 × 105 (day 21) copies/ml.
Also, the BM aspirate showed 4.1 × 105 EBV copies/ml.
These changes correlated with an improvement in clinical
status and blood analysis: WBC 5.14 × 109/L, neutrophils
2.78 × 109/L, lymphocytes 0.92 × 109/L, platelets 45 × 109/L,
hemoglobin 8.9 g/dl (not dependent on blood or platelet
transfusions), TB 1.10mg/dl, AST 37 IU/L, ALT 39 IU/L, GGT
71 IU/L, and LDH 425 IU/L. A second evaluation of the
BM aspirate after the second GEM-P showed only 0.09%
of neoplastic NK cells. At that time, the BM biopsy pro-
vided evidence for a partial hematopoietic recovery, although
intrasinusoidal niches of neoplastic NK cells were still
observed; in addition, the BMkaryotype was again abnormal,
with different chromosomal aberrancies: 77,add(X)(q27),-
Y,i(7)(q10),inc[5]/46,XY[15]. Similarly, an increase of the
EBV load was observed (42 × 105 copies/ml). Considering
the refractoriness to GEM-P, it was decided to change the
chemotherapy.
Nearly one month later, when the alternative schema
was being discussed, the patient was admitted to urgency
reporting loss of vision. At that time, the ophthalmologic and
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Figure 1:Thoracic-abdominal-pelvic computerized tomography scan showing the hepatosplenomegaly (liver and spleen longitudinal axis of
209 cm and 158 cm, resp.), without other significant abnormalities (a). Cerebral MR images showing swelling of the left lateral rectus muscle
on a T2-weighted image, with no other additional findings (b).
Figure 2: Bone marrow cytomorphology findings. Composite
image of circulating leukemic cells obtained from Wright-Giemsa-
stained peripheral blood smears.
neurological examination revealed an almost total bilateral
decline in visual acuity, markedly decreased pupil reflexes,
right retinal detachment, and impaired right eye abduction
compatible of palsy of the 6th right cranial nerve. Blood
analyses were as follows:WBC 4.78×109/L, neutrophils 2.14×
109/L, lymphocytes 1.69 × 109/L, and platelets 155 × 109/L,
depending on regular blood transfusions, TB 0.88mg/dl, AST
34U/L, ALT 29U/L, and LDH 429 IU/L. Abnormal NK cells
had increased in blood (1.9% by FCM) and there was a
marked increment on the EBV load (89 × 105 copies/ml) and
on the LDH (1587 IU/L). Head CT revealed a thickening of
the right optic nerve, compatible with neoplastic infiltration,
without evidence for other abnormalities in brain tissue
and structures. Five days later he also developed dysphonia,
dysphagia, impaired abduction of the left eye, and left eyelid
ptosis and the headMRI showed a thickening of the left lateral
rectus muscle (Figure 1(b)). At that time, there was clinical
evidence of palsy of multiple cranial nerves (bilateral palsy
of the 2nd and 8th left and right cranial pares, left palsy
of the 3rd and 5th left cranial pares, and right palsy of the
6th and 7th right cranial pares). The CSF had 262 cells/𝜇l
with 88% of atypical mononuclear cells, being consistent with
leukemia meningitis. Immunophenotypic characterization
was not performed, as on the day of the lumbar puncture
flow cytometrywas not available at our institution; EBVDNA
analysis was not possible due to insufficient sample volume.
At this point, no further chemotherapywas administered, and
the strategy from here on was best supportive care. Death
occurred a few days later, 107 days after the diagnosis.
3. Discussion and Conclusions
ANKL is an extremely rare and aggressive lymphoid neo-
plasm characterized by a proliferation of EBV-transformed
mature NK cells, with a higher incidence in Asia and Central
and South America [9]. A review of 73 cases of ANKL
published in the English literature, from 1966 to 2003,
reported a median age of 37 years at diagnosis and a slight
male predominance, alongside acute onset of symptoms and
a median survival of 61 days [10]. The largest series were
published in 2004 [9] and 2013 [11], and they included only
22 and 43 patients, from Japan and China, respectively. To
date, only around one hundred cases have been reported all
over the world and the main disease manifestations are in
concordance with the patient presented herein. Comparable
clinical and pathological features were observed in 3 cases of
EBV-negative ANKL that were recently reported [12].
Similarly to that typically found in other ANKL cases,
our patient was very ill, with fever, cytopenias, liver function
disturbances, and high levels of serum LDH; and, as in other
ANKL cases, the disease affected mainly the BM and the PB,
as well as the liver and the spleen. During the disease course,
disseminated intravascular coagulation and hemophagocytic
syndrome (HS) develop frequently, and multiorgan failure
finally culminates with death. Unfortunately, the possibility
of our patient having aHSwas not considered at the diagnosis
and, therefore, the criteria for diagnosis of HS were not
fully evaluated [13]. Analyzing retrospectively, we verify that
although some criteria for HS were present (splenomegaly,
periods of fever ≥ 38.5∘, and pancytopenia), some were not
4 Case Reports in Hematology
T cells: 2%
B cells: 1%
NK cells: 87% 
Other cells: 10%
Figure 3: Flow cytometry studies in the bonemarrow aspirate, using the EuroFlow lymphoid screening tube (LST) and antibody panel for NK
cell chronic lymphoproliferative diseases (NK-CLPD), consisting of 8-color combinations of monoclonal antibodies (7), and a FACSCanto
II flow cytometer (Becton Dickinson). Data analysis was performed using the Infinicyt software (Cytognos, Spain). Dot-plots illustrate the
phenotypic features of the neoplastic NK cells. Blue dots correspond to the neoplastic NK cells whereas pink dots and yellow dots are the
normal residual T cells and B cells present in the bone marrow sample. Other cells are represented as gray dots. The abnormal NK cells were
positive for surface CD45 (high), CD2, CD26, CD38, CD94 (high), and HLA-DR and cytoplasmic granzyme B and perforin; and they were
negative for surface CD3, CD4, CD5, CD7, CD8, CD11c, CD16, CD19, CD20, CD25, CD56, Ig kappa, and lambda chains.
met (fibrinogen < 150mg/dl and evidence of hemophago-
cytosis in the BM and liver) and others were not evaluated
(ferritin, fasting triglycerides, NK cell activity, and soluble
CD25).The available data applied to the HScore proposed by
Fardet et al. corresponds to a probability of 30.1% of having
HS [14]. In our patient, the final event was leukemic menin-
gitis. Meningeal infiltration may be diffuse or focal, and it
may manifest as signals/symptoms of increased intracranial
pressure, visual disturbances, or cranial nerves paralysis. It
may occur as part of the initial presentation of ANKL was
previously documented in two published cases of ANKL
with polycranial nerve palsies and peripheral neuropathy
andmeningitis [15, 16]; more commonly, however, meningeal
spread occurs in the form of relapse, as in our patient.
The immunophenotype of ANKL cells is indistinguishable
from that observed in ENKTL for the majority of the
currently usedmarkers, and previously published data would
suggest that both diseases originate from CD56+high and
CD16−/+low NK cells in most cases [17]. Lack of expression
of CD56 observed in this case is uncharacteristic and may
indicate a more immature NK cell immunophenotype, as
more than 80% of the ANKL and ENKTL cases described
to date were found to be CD56+; in addition, as in this case,
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Figure 4: Bonemarrowhistological findings. Bonemarrowbiopsy sectionWright-Giemsa stained (40x) (a).The lymphoid infiltrate is positive
for CD3 epsilon (b) and negative for CD56 (c). In situ hybridization showing positivity of the neoplastic cells for EBER (d).
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Figure 5: Bone marrow karyotype with chromosome banding analysis with complex aberrancies: 46,add(X)(q27),-Y,
i(7)(q10),+8,add(17)(p13),add(19)(q13). Arrows indicate the chromosomal abnormalities.
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most of the cases tested stained positively for surface CD2, as
well as for cytoplasmic (but not surface) CD3𝜀 and cytotoxic
granule molecules, and about one-quarter of the ENKTL and
half of ANKL cases are CD16+ [17].
A few cases of CD56-negative ENKTLhave been reported
in the literature [18–25] and case series have included some
patients with CD56-negative ENKTL [26–28]. Li et al. found
CD56 to be expressed in 90 of 118 (76.3%) patients with
ENKTL and that the majority (83.3%) of patients with nasal
ENKTL presented with CD56+ lymphoma, whereas patients
with extranasal ENKTL of the upper aerodigestive tract were
more likely to have CD56-negative tumors (53.6%) [26]. In a
large cohort of 288 patients with early-stage ENKTL affecting
the upper aerodigestive tract, fromwhich 60 patients (20.8%)
were categorized as CD56 negative, Wang et al. observed
that CD56-negative ENKTL cases had significantly inferior
survival outcomes [28]. In accordance, patients with CD56-
negative ENKTL had significantly lower complete remission
rates as compared to patients with CD56-positive ENKTL
(60.8% versus 80.6%, resp.) and significantly lower 5-year and
10-year progression-free survival (PFS) and overall survival
(OS) rates; furthermore, CD56 expression status proved to be
an independent prognostic factor for PFS and had a trend to
be independently correlated with OS [28].
To the best of our knowledge, so far, no individual cases
of CD56 negative ANKL have been previously described
in the literature, although a rare case of aggressive T cell
large granular lymphocyte leukemia was recently reported
[29], and a case series have revealed strong CD56 positivity
in all but 5 cases of 43 (88.4%) of ANKL tested by flow
cytometry (11). The only case of ANKL published in Portugal
was not tested for CD56 expression [30]. Absence of CD56
expression imposes diagnostic difficulties, as the phenotypic
criteria routinely used to identify NK cells usually rely on
the positivity for CD56. In addition, NK cell neoplasms
are sometimes erroneously classified as T cell neoplasms in
BM and tissue biopsies, as NK cells frequently have epsilon
chains of CD3 in the cytoplasm and, therefore, they may
stain positively for CD3 in immunohistochemistry of paraffin
sections [31].
The neoplastic NK cells are almost invariably latently
infected with the EBV, thereby expressing the EBER-1 and
EBER-2, the EBV nuclear antigen 1, and, usually, the latent
membrane proteins 1 and 2, detected by in situ hybridization
or immunohistochemistry on tissue biopsies, respectively. As
in the case reported herein, high levels of EBV DNA copies
are usually found in the blood [11], and the viral load can
be followed up over time using quantitative PCR assays, as
previously described for posttransplant lymphoproliferative
disorders [32]. Overall, the EBV infection was documented
in more than 85% of ANKL cases.
Currently, genetic abnormalities specific for ENKTL and
ANKL have not yet been identified, although complex chro-
mosomal aberrancies occur in a large fraction of cases [33].
Loss of heterozygosity at chromosomes 6q, 13q, 11q, and
17p is frequent [34], with a recurrent deletion on 6q in the
target area 6q21–25 [35]. Consequently, multiple genes are
affected, often due to gene deletion,mutation, ormethylation,
which include tumor suppressor genes and oncogenes [36].
An array-based comparative genomic hybridization study
indicates that the genetic aberrancies recurrently observed
in ANKL, which include loss of 7p15.1–p22.3 and 17p13.1
and gain of 1q, are different from those found in ENKTL
[37]. Among the complex karyotype abnormalities found in
our patient, the gain of genetic material on chromosomes
17p13 and 19q13 and the isochromosome 7q might affect
genes known to be involved in a wide variety of human
cancers. For instance, genes located at 17p13.1 include those
codifying for the aurora kinase B (AURKB), a centrosome-
associated kinase that plays an important role as regulator of
chromosome segregation and cytokinesis, and, for the tumor
protein p53, a protein that causes cells with damaged DNA to
arrest at the G1 phase of cell cycle (TP53). Deletions on TP53,
a tumor suppressor gene, are frequently found in neoplastic
NK cells and have been associated with more advanced
disease, suggesting a secondary oncogenic event rather than
a triggering mechanism [38]. In addition, genes located at
the 19q13 are the BAX and BCL3 apoptosis related genes
[39], genes involved in cell cycle progression that codify for
cyclins, such asCCNE1, and genes codifying for transcription
factors, such as FOSB [40], among others [41]. Finally, the
isochromosome 7q, the primary cytogenetic abnormality
in hepatosplenic gamma/delta T cell lymphoma, where the
TCRB gene located at 7q35 is affected, was also previously
described in 2 cases of ENKTL [42].
Although some treatment algorithms have been proposed
for ENKTL and ANKL [43], there is no curative and uni-
formly accepted approach [44, 45]. Standard anthracycline-
based schemas such as CHOP (cyclophosphamide, doxoru-
bicin, vincristine, and prednisone) are known to be inef-
fective, due to the expression of proteins associated with
multidrug resistance [46, 47]. L-Asparaginase, etoposide,
and methotrexate based schemas, such as the SMILE regi-
men (steroids, methotrexate, ifosfamide, L-asparaginase, and
etoposide), have shown promising results [48, 49], and a
phase II study for evaluating the effectiveness of the associa-
tion of L-asparaginase, methotrexate, and dexamethasone for
relapsing and/or refractory ENKTL has recently been done
[50].
This patient was refractory to GEM-P, a gemcitabine and
cisplatin-based schema that was previously tested in patients
with peripheral T cell lymphoma, with encouraging results
and acceptable toxicity [8]. An observational retrospective
study on the use of gemcitabine in pretreated/refractory
ENKTL has been recently completed, but the results are
not yet available so far [51]; in addition two randomized
controlled multicenter clinical trials are now evaluating the
efficacy of the DDGP (gemcitabine, pegaspargase, cisplatin,
and dexamethasone) regimen for patients with ENKTL [52,
53]. The role of stem cell transplantation in the treatment of
theNK cell neoplasms has been studied retrospectively by the
NK cell Tumor Study Group; results have indicated a possible
beneficial effect, but the criteria for transplantation were not
uniformly accepted [54]. Investigations on future therapies
are under progress and possible targets include survivin
[55, 56] and the AURKA (Aurora Kinase A) and NOTCH-
1 (Notch Homologue 1) oncogenic pathways [57]; modula-
tion of gene expression with hypomethylating agents [58],
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immunoconjugates of anti-CD56 monoclonal antibodies
[59], and inhibitors of tubule polymerization [42] are other
possibilities.
In conclusion, the rarity of the ANKL and its clinical
aggressiveness limit our ability to standardize the procedures
for the diagnosis and clinical management and efforts should
be made to encourage multi-institutional registries and clini-
cal trials. CD56-negative cases impose diagnostic difficulties,
being correctly diagnosed only if the immunophenotype of
the neoplastic cells is exhaustively studied.
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